Status:
COMPLETED
Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
Lead Sponsor:
Research in Real-Life Ltd
Collaborating Sponsors:
Chiesi Farmaceutici S.p.A.
Conditions:
Asthma
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropiona...
Eligibility Criteria
Inclusion
- Aged:
- 18-60 years:
- 61-80 years who are never-smokers
- Evidence of asthma:
- a diagnostic code for asthma, or
- ≥2 prescriptions for asthma at different points in time during the prior year
- Baseline FP/SAL therapy:
- ≥2 prescription for ICS/LABA therapy as FP/SAL (Seretide® 125).
Exclusion
- Any chronic respiratory disease other than asthma
- Are receiving maintenance oral steroid therapy during baseline period.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT01242098
Start Date
January 1 2008
End Date
December 1 2011
Last Update
June 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Optimum Patient Care
Cawston, Norfolk, United Kingdom, NR10 4FE